CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities

Area of Science:

• Genetics
• Molecular Biology
• Biotechnology

Background:

• Myotonic dystrophy type 1 (DM1) is a severe, inherited neuromuscular disorder with no current cure.
• The disease is caused by an unstable (CTG•CAG)n repeat expansion in the DMPK gene.
• This expansion leads to DNA, RNA, and protein level toxicity, affecting cellular homeostasis.

Purpose of the Study:

• To review CRISPR/Cas-mediated approaches for treating DM1.
• To evaluate strategies targeting the causative (CTG•CAG)n repeat in DNA and RNA.
• To compare DM1 CRISPR developments with those in other microsatellite instability diseases.

Main Methods:

• CRISPR/Cas9 dual cleavage for triplet repeat excision from the genome.
• Homology-directed insertion of a polyadenylation signal to prevent transcription.
• Recruitment of catalytically deficient Cas9 (dCas9) to block RNA polymerase II.
• Utilizing dCas9-RNase fusion to degrade expanded (CUG)n RNA.

Main Results:

• CRISPR/Cas9 successfully excised the expanded triplet repeat in multiple studies.
• Transcriptional interference was achieved by inserting a polyadenylation signal.
• dCas9 and dCas9-RNase fusions demonstrated efficacy in targeting RNA and blocking transcription.

Conclusions:

• CRISPR/Cas technology shows significant promise for developing DM1 therapies.
• Multiple strategies targeting DNA and RNA offer potential therapeutic avenues.
• Overcoming existing hurdles is crucial for translating CRISPR-based editing into clinical applications for DM1 patients.